Growth factors

BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 10, 2020

The combination of plinabulin with pegfilgrastim represents a major advancement in offering protection against CIN, with the potential to reduce FN risk, in the care of cancer patients.

Key Points: 
  • The combination of plinabulin with pegfilgrastim represents a major advancement in offering protection against CIN, with the potential to reduce FN risk, in the care of cancer patients.
  • The data were presented via a poster at the 2020 San Antonio Breast Cancer Symposium (SABCS): Superior and Clinically Meaningful Protection Against Profound Neutropenia with the Plinabulin/Pegfilgrastim (Plin/Peg) Combination versus Peg In Breast Cancer Patients ReceivingTAC Chemotherapy.
  • It is attributed to both febrile neutropenia (48%) and infection (50%) [Bodey Cancer 1978].
  • Topline data from the Protective-2 Phase 3 trial were reported on November 16, 2020 highlighting that the study met its primary endpoint as well as key secondary endpoints.

Use of ViviGen® Cellular Bone Matrix results in significantly lower hospital costs compared to rhBMP-2

Retrieved on: 
Monday, November 23, 2020

VIRGINIA BEACH, Va., Nov. 23, 2020 /PRNewswire/ -- ViviGen Cellular Bone Matrix is associated with significantly lower hospital costs compared torecombinant human bone morphogenetic protein-2 (rhBMP-2), according to an analysis of more than 16,000 U.S. lumbar fusions procedures.

Key Points: 
  • VIRGINIA BEACH, Va., Nov. 23, 2020 /PRNewswire/ -- ViviGen Cellular Bone Matrix is associated with significantly lower hospital costs compared torecombinant human bone morphogenetic protein-2 (rhBMP-2), according to an analysis of more than 16,000 U.S. lumbar fusions procedures.
  • The data shows that ViviGen provides hospitals with a fusion solution that is more cost effective than rhBMP-2.
  • "These results emphasize the true economic advantages it offers as well, bringing together successful outcomes and drastically lower costs."
  • ViviGen is the first cellular allograft to focus on recovering and protecting viable, lineage-committed bone cells to support the bone-healing process.

BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia

Retrieved on: 
Monday, November 16, 2020

The PROTECTIVE-2 Phase 3 study is a double-blind, active-controlled, global study that enrolled a total of 221 patients.

Key Points: 
  • The PROTECTIVE-2 Phase 3 study is a double-blind, active-controlled, global study that enrolled a total of 221 patients.
  • Plinabulin in combination with pegfilgrastim showed a statistically significant improvement compared to pegfilgrastim alone, with topline data summarized below.
  • Grade 4 neutropenia is also associated with increased mortality and reduced long-term survival due to reduction, delay, or interruption of chemotherapy.
  • This is a superiority study in CIN efficacy in the rate of prevention of Grade 4 neutropenia, comparing the combination head-to-head against Pegfilgrastim alone.

BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations

Retrieved on: 
Friday, November 13, 2020

BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Centers Therapeutics Discovery division .

Key Points: 
  • BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Centers Therapeutics Discovery division .
  • Part 1 is a dose escalation to establish the recommended Phase 2 dose (RP2D) of BBP-398.
  • Part 2 will examine preliminary anti-tumor activity in four cohorts of patients with certain molecular alterations.
  • As SHP2 regulates receptor tyrosine kinase signaling pathways commonly overly activated in cancer, targeting SHP2 may offer a potential new approach to treat this disease.

Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting

Retrieved on: 
Monday, November 9, 2020

[NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting.

Key Points: 
  • [NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting.
  • For more details on the abstract and the oral presentation, see below.
  • Title: Pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) with standard chemoradiotherapy/adjuvant temozolomide for glioblastoma multiforme (GBM) patients: ReoGlio phase I trial results.
  • The primary objective of the study was to determine the maximum tolerated dose of pelareorep and GM-CSF with standard chemoradiotherapy.

Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting

Retrieved on: 
Monday, November 9, 2020

[NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting.

Key Points: 
  • [NASDAQ: ONCY] [TSX: ONC] today announced the publication of an abstract for an oral presentation to be given as part of the virtual 2020 Society of Neuro-Oncology (SNO) Annual Meeting.
  • For more details on the abstract and the oral presentation, see below.
  • Title: Pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) with standard chemoradiotherapy/adjuvant temozolomide for glioblastoma multiforme (GBM) patients: ReoGlio phase I trial results.
  • The primary objective of the study was to determine the maximum tolerated dose of pelareorep and GM-CSF with standard chemoradiotherapy.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Friday, November 6, 2020

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia.

Cerapedics Announces Commercial Launch of i-FACTOR®+ Matrix in Canada

Retrieved on: 
Thursday, November 5, 2020

WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ --Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada.

Key Points: 
  • WESTMINSTER, Colo., Nov. 5, 2020 /PRNewswire/ --Cerapedics, a private ortho-biologics company, today announced the full commercial availability of i-FACTOR+ MATRIX for surgical implantation in Canada.
  • "Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling."
  • i-FACTOR+ MATRIX utilizes a small proprietary peptide (P-15) technology developed by Cerapedics to support bone growth through cell attraction, attachment, and activation.
  • "In addition to the commercial launch in Canada, the latest i-FACTOR+ MATRIX generation is currently being studied in our FDA IDE study, ASPIRE, targeting lumbar fusions (TLIF), as previously announced.

Humanigen to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, October 27, 2020

A live webcast of the presentation may be accessed on the Events section of the Humanigen website https://www.humanigen.com/events .

Key Points: 
  • A live webcast of the presentation may be accessed on the Events section of the Humanigen website https://www.humanigen.com/events .
  • Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Retrieved on: 
Monday, October 26, 2020

In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).

Key Points: 
  • In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).
  • The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.
  • Dr. Laurenz Kellenberger, Chief Scientific Officer, said: Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors.
  • The preclinical data on derazantinibs anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors.